Azure Minerals Strikes Silver and Gold in Mexico

Source: The Gold Report  (08/25/2016)
Azure Minerals Strikes Silver and Gold in Mexico
Azure Minerals Ltd. (AZS:ASX), an Australian company developing two precious metal projects in Mexico, has caught the attention of a pair of analysts and the Mining Journal. read more >

Pan Orient Energy's Exploration Drilling Set to Commence Q4/16

Source: The Energy Report  (08/25/2016)
Pan Orient Energy's Exploration Drilling Set to Commence Q4/16
Pan Orient Energy's strong balance sheet puts it in position to begin drilling at East Jabung in Indonesia at the end of this year. read more >

Inovio Expands Ebola Vaccine Trial

Source: The Life Sciences Report  (08/24/2016)
Inovio Expands Ebola Vaccine Trial
Inovio Pharmaceuticals Inc. (INO:NASDAQ) has expanded the Phase 1 trial of its Ebola vaccine to include an additional 125 healthy subjects. This, according to Maxim Group analyst Jason Kolbert, will help the company determine an "optimal" strategy for intradermal (skin) vaccination. read more >

A Zombie Financial System, Black Swans and a Gold Share Correction

Contributed Opinion
Source: Bob Moriarty for The Gold Report  (08/23/2016)
A Zombie Financial System, Black Swans and a Gold Share Correction
Bob Moriarty of 321Gold says that since the crash of 2008, the financial system has become a zombie, and he urges investors to pay attention to when they take some money off the table. read more >

Investing in the New Resource Bull Market

Source: Matt Geiger for The Gold Report  (08/22/2016)
Investing in the New Resource Bull Market
After four grinding years of falling metal prices and vanishing market capitalizations, we have seen a stunning shift in market sentiment since mid-January, says Matt Geiger of MJG Capital. Multiple physical commodities are now in technical bull markets, and resource equities in particular have enjoyed a spectacular 2016 thus far. Geiger highlights several companies poised to take advantage of the boom. read more >

Novo Resources Aims for High-Grade Gold Trifecta

Contributed Opinion
Source: Bob Moriarty for The Gold Report  (08/21/2016)
Novo Resources Aims for High-Grade Gold Trifecta
Bob Moriarty of 321 Gold, who has been following Novo Resources for four years, discusses the company's three programs that are likely to gain investor attention. read more >

Nailing the Bottom of Oil

Contributed Opinion
Source: Bob Moriarty for The Energy Report  (08/21/2016)
Nailing the Bottom of Oil
Bob Moriarty points investors toward information that accurately captures movement in energy markets. read more >
Expert Investing Ideas

"We recommend NXE, our top uranium exploration pick."

–David Talbot, Dundee Capital Markets


"The time for POE is finally coming, should be the next 6-12 months."

–Chen Lin, What Is Chen Buying? What Is Chen Selling?


Gold Ready to Correct

Contributed Opinion
Source: Jack Chan for The Gold Report  (08/20/2016)
Gold Ready to Correct
No bull market is sustainable on a nonstop price spike, says technical analyst Jack Chan, and he predicts the current gold bull market will soon correct, providing a good entry point. read more >

The Buy Signal for Oil Is In

Contributed Opinion
Source: Jack Chan for The Energy Report  (08/20/2016)
The Buy Signal for Oil Is In
Technical analyst Jack Chan documents a major new buy signal for oil stocks and ETFs that will enable investors to hold for the long term. read more >

Tahoe Resources' Record-Setting Quarter Earns Analysts' Praise

Source: The Gold Report  (08/18/2016)
Tahoe Resources' Record-Setting Quarter Earns Analysts' Praise
The Q2 numbers are in, and Tahoe Resources exceeded both production and cash flow expectations in the first half of 2016, according to analysts following the company. Based on those numbers—and with management changes also in place—the experts believe the company will continue to outperform. read more >
Management Q&A: View from the Top

Radioimmunotherapy 2.0: Actinium Sets Eyes on Bone Marrow Transplant and AML with Later-Stage Programs

Managment Q&A: View from the Top
Source: The Life Sciences Report  (08/17/2016)
Radioimmunotherapy 2.0: Actinium Sets Eyes on Bone Marrow Transplant and AML with Later-Stage Programs
Radioimmunotherapy is experiencing a renaissance, and Actinium Pharmaceuticals Inc. is in position to benefit, according to company executive chairman Sandesh Seth. With two assets targeting treatment of AML in older adults in clinical trials, and a platform primed to "nuke cancer," the company has a number of milestones in its near future that investors should be watching. read more >